RIGL - Rigel Pharmaceuticals Inc Stock Price, Fair Value and News

0.99USD-0.20 (-16.81%)Market Closed

Market Summary

USD0.99-0.20

Market Closed

-16.81%

RIGL Stock Price

View Fullscreen

RIGL RSI Chart

RIGL Valuation

Market Cap

173.7M

Price/Earnings (Trailing)

-8.77

Price/Sales (Trailing)

1.44

EV/EBITDA

-9.1

Price/Free Cashflow

-25.99

RIGL Price/Sales (Trailing)

RIGL Profitability

EBT Margin

-20.85%

Return on Equity

62.52%

Return on Assets

-15.65%

Free Cashflow Yield

-3.85%

RIGL Fundamentals

RIGL Revenue

Revenue (TTM)

120.3M

Rev. Growth (Yr)

13.29%

Rev. Growth (Qtr)

-17.48%

RIGL Earnings

Earnings (TTM)

-19.8M

Earnings Growth (Yr)

39.07%

Earnings Growth (Qtr)

-1.2K%

Breaking Down RIGL Revenue

Last 7 days

-9.2%

Last 30 days

-21.4%

Last 90 days

-13.2%

Trailing 12 Months

-14.7%

How does RIGL drawdown profile look like?

RIGL Financial Health

Current Ratio

1.26

RIGL Investor Care

Shares Dilution (1Y)

1.00%

Diluted EPS (TTM)

-0.11

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	120.3M	0	0	0
2023	129.6M	126.6M	132.4M	116.9M
2022	85.0M	88.5M	89.4M	120.2M
2021	133.9M	144.1M	147.3M	149.2M
2020	102.4M	108.0M	105.6M	108.6M
2019	57.1M	65.8M	81.7M	59.3M
2018	0	2.7M	7.6M	44.5M
2017	18.9M	10.3M	7.5M	4.5M
2016	31.7M	35.2M	25.9M	20.4M
2015	16.2M	21.4M	28.6M	28.9M
2014	0	0	0	15.4M
2013	0	2.9M	1.4M	7.2M
2012	5.7M	6.6M	2.3M	2.3M
2011	0	84.9M	44.8M	4.8M
2010	0	0	0	125.0M
2009	0	0	0	0

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Rigel Pharmaceuticals Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Feb 05, 2024	santos david a	sold	-10,166	1.14	-8,918	evp, chief commercial officer
Feb 05, 2024	schorno dean l	sold	-8,010	1.14	-7,027	evp & chief financial officer
Feb 05, 2024	rodriguez raul r	sold	-34,821	1.14	-30,545	ceo, president
Feb 02, 2024	santos david a	sold	-6,329	1.13	-5,601	evp, chief commercial officer
Feb 02, 2024	schorno dean l	sold	-6,326	1.1296	-5,601	evp & chief financial officer
Feb 02, 2024	rodriguez raul r	sold	-25,261	1.1303	-22,349	ceo, president
Jan 23, 2024	santos david a	acquired	-	-	209,000	evp, chief commercial officer
Jan 23, 2024	furey raymond j.	acquired	-	-	209,000	evp, gc, cco & corp sec
Jan 23, 2024	schorno dean l	acquired	-	-	209,000	evp & chief financial officer
Jan 23, 2024	rodriguez raul r	acquired	-	-	400,000	ceo, president

Which funds bought or sold RIGL recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 07, 2024	SUSQUEHANNA INTERNATIONAL GROUP, LLP	reduced	-55.34	-236,690	198,249	-%
May 07, 2024	NEW YORK STATE COMMON RETIREMENT FUND	reduced	-0.73	1,000	49,000	-%
May 06, 2024	Advisory Services Network, LLC	sold off	-100	-3,915	-	-%
May 06, 2024	STONERIDGE INVESTMENT PARTNERS LLC	new	-	46,000	46,000	0.02%
May 06, 2024	HighTower Advisors, LLC	new	-	13,000	13,000	-%
May 06, 2024	SG Americas Securities, LLC	reduced	-55.33	-39,000	33,000	-%
May 03, 2024	VICTORY CAPITAL MANAGEMENT INC	reduced	-2.19	-56.00	33,503	-%
May 03, 2024	HUNTINGTON NATIONAL BANK	added	53,900	798	799	-%
May 03, 2024	GSA CAPITAL PARTNERS LLP	reduced	-3.33	-27,000	2,042,000	0.16%
May 02, 2024	NISA INVESTMENT ADVISORS, LLC	added	220	443	639	-%

Are Funds Buying or Selling RIGL?

Are funds buying RIGL calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own RIGL

No. of Funds

Unveiling Rigel Pharmaceuticals Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	armistice capital, llc	9.81%	17,100,000	SC 13G/A
Feb 13, 2024	vanguard group inc	5.13%	8,953,217	SC 13G/A
Feb 09, 2024	morgan stanley	8.3%	14,490,600	SC 13G
Feb 05, 2024	goldman sachs group inc	0.1%	255,676	SC 13G/A
Feb 02, 2024	soleus capital master fund, l.p.	5.4%	9,442,579	SC 13G/A
Jan 25, 2024	blackrock inc.	8.7%	15,198,077	SC 13G/A
Jun 12, 2023	fmr llc	-	0	SC 13G/A
Feb 22, 2023	soleus capital master fund, l.p.	5.3%	9,223,015	SC 13G
Feb 14, 2023	armistice capital, llc	9.81%	16,956,000	SC 13G
Feb 14, 2023	goldman sachs group inc	5.4%	9,370,063	SC 13G

Recent SEC filings of Rigel Pharmaceuticals Inc

View All Filings

Date Filed	Form Type	Document
May 07, 2024	10-Q	Quarterly Report
May 07, 2024	8-K	Current Report
Apr 12, 2024	8-K	Current Report
Apr 10, 2024	ARS	ARS
Apr 10, 2024	DEF 14A	DEF 14A
Apr 10, 2024	DEFA14A	DEFA14A
Mar 29, 2024	3	Insider Trading
Mar 29, 2024	4	Insider Trading
Mar 29, 2024	PRE 14A	PRE 14A
Mar 05, 2024	10-K	Annual Report

Peers (Alternatives to Rigel Pharmaceuticals Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	46.7B	6.8B	16.03%	-8.84%	-7.83	6.82	-64.45%	-224.75%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	19.3B	2.0B	-2.41%	-26.73%	-58.01	9.62	75.20%	68.82%
BMRN	15.5B	2.5B	-6.28%	-14.44%	75.6	6.28	13.74%	186.89%
INCY	12.0B	3.8B	-2.82%	-17.40%	16.12	3.19	8.58%	129.81%
MID-CAP
BBIO	5.2B	107.9M	-2.02%	101.31%	-9.48	48.09	54.84%	-28.31%
APLS	5.1B	524.1M	-21.41%	-52.73%	-12.3	9.79	394.93%	39.61%
AXSM	3.6B	251.0M	5.14%	-1.20%	-12.15	14.35	73.58%	-86.73%
ARWR	3.1B	240.7M	-1.87%	-37.68%	-10.53	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-3.99%	-20.25%	-45.95	3.88	40.45%	71.62%
SMALL-CAP
CPRX	1.7B	411.3M	-5.16%	-15.46%	26.68	4.22	60.38%	-34.49%
NVAX	625.6M	983.7M	0.90%	-53.05%	-1.15	0.64	-50.36%	17.16%
CRBP	451.6M	881.7K	5.23%	376.44%	-13.38	481.06	-77.61%	33.36%
INO	257.1M	4.9M	-3.00%	9.13%	-1.9	52.83	-54.97%	51.71%
IBIO	6.6M	2.1M	-15.93%	74.31%	-0.24	2.14	-13.45%	66.37%

Rigel Pharmaceuticals Inc News

Latest updates

Rigel Pharmaceuticals Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	-17.5%	29,534,000	35,792,000	28,134,000	26,886,000	26,070,000	51,278,000	22,410,000	29,819,000	16,735,000	20,409,000	21,543,000	26,266,000	81,018,000	18,450,000	18,389,000	16,021,000	55,761,000	15,400,000	20,857,000	10,407,000	12,624,000
Costs and Expenses	7.9%	36,500,000	33,826,000	32,599,000	32,153,000	38,795,000	49,199,000	40,813,000	42,784,000	42,996,000	41,827,000	41,328,000	39,314,000	39,263,000	37,277,000	32,170,000	33,413,000	34,734,000	32,737,000	32,894,000	31,746,000	31,002,000
S&GA Expenses	6.0%	28,449,000	26,850,000	24,856,000	26,306,000	27,729,000	32,172,000	25,897,000	26,981,000	27,401,000	24,515,000	22,877,000	22,378,000	22,121,000	21,818,000	17,430,000	18,920,000	18,430,000	18,312,000	18,121,000	18,209,000	19,946,000
EBITDA Margin	7.0%	-0.14	-0.15	-0.39	-0.41	-0.41	-0.45	-0.87	-0.89	-0.93	-0.08	-0.06	-0.02	-	-	-	-	-	-	-	-	-
Interest Expenses	-1.7%	1,874,000	1,907,000	1,899,000	1,862,000	1,204,000	1,107,000	826,000	569,000	1,205,000	1,299,000	1,317,000	1,759,000	485,000	429,000	429,000	353,000	142,000	327,000	8,000	-	-
Income Taxes	-	-	-	-	-	-	-	-	-	-	-100,000	-100,000	-1,000,000	1,800,000	-	-	-	-	-	-	-	-
Earnings Before Taxes	-	-	-	-	-	-	1,401,000	-19,037,000	-13,492,000	-27,445,000	-22,701,000	-21,088,000	-14,791,000	41,271,000	-19,237,000	-14,174,000	-17,576,000	21,243,000	-	-	-	-
EBT Margin	2.9%	-0.21	-0.21	-0.44	-0.46	-0.45	-0.49	-0.93	-0.96	-1.01	-0.12	-0.09	-0.05	-	-	-	-	-	-	-	-	-
Net Income	-1219.0%	-8,247,000	737,000	-5,692,000	-6,600,000	-13,536,000	1,401,000	-19,037,000	-13,492,000	-27,445,000	-22,641,000	-20,952,000	-13,821,000	39,500,000	-19,237,000	-14,174,000	-17,576,000	21,243,000	-17,200,000	-11,490,000	-20,606,000	-17,598,000
Net Income Margin	23.4%	-0.16	-0.21	-0.18	-0.30	-0.34	-0.49	-0.92	-0.96	-1.00	-0.12	-0.10	-0.05	-	-	-	-	-	-	-	-	-
Free Cashflow	19.4%	-5,086,000	-6,313,000	-1,432,000	5,857,000	-4,147,000	-21,982,000	-13,490,000	-12,875,000	-25,861,000	-19,065,000	-10,467,000	54,809,000	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	7.9%	127	117	115	117	124	134	116	128	149	167	187	202	216	110	123	138	143	148	156	156	173
Current Assets	-6.8%	92.00	99.00	95.00	101	107	116	110	121	139	154	171	184	197	89.00	100	113	116	119	126	125	139
Cash Equivalents	-22.0%	26.00	33.00	45.00	49.00	40.00	24.00	30.00	27.00	25.00	19.00	30.00	85.00	20.00	30.00	37.00	36.00	45.00	23.00	39.00	44.00	75.00
Inventory	19.1%	7.00	6.00	6.00	11.00	11.00	9.00	7.00	6.00	7.00	7.00	7.00	7.00	7.00	2.00	2.00	2.00	2.00	1.00	1.00	1.00	1.00
Net PPE	-15.2%	0.00	0.00	0.00	0.00	0.00	1.00	2.00	2.00	2.00	2.00	3.00	3.00	2.00	3.00	3.00	2.00	3.00	2.00	2.00	2.00	2.00
Liabilities	8.4%	158	146	147	145	148	148	-	-	-	137	-	-	-	-	-	-	-	-	-	-	-
Current Liabilities	37.4%	73.00	53.00	48.00	44.00	46.00	65.00	47.00	55.00	59.00	64.00	59.00	60.00	52.00	41.00	34.00	35.00	31.00	58.00	31.00	28.00	26.00
Shareholder's Equity	-10.6%	-31.67	-28.64	-	-	-24.26	-13.62	-	-	7.00	30.00	50.00	68.00	78.00	34.00	51.00	63.00	78.00	54.00	69.00	78.00	95.00
Retained Earnings	-0.6%	-1,415	-1,407	-1,408	-1,402	-1,395	-1,382	-1,383	-1,364	-1,351	-1,323	-1,301	-1,280	-1,266	-1,305	-1,286	-1,272	-1,254	-1,276	-1,259	-1,247	-1,226
Additional Paid-In Capital	0.4%	1,384	1,379	1,376	1,374	1,372	1,369	1,364	1,361	1,358	1,354	1,351	1,348	1,345	1,340	1,338	1,336	1,333	1,330	1,328	1,326	1,322
Shares Outstanding	0.2%	175	175	174	174	174	173	173	172	172	170	171	170	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	223	-	-	-	194	-	-	-	740	-	-	-	309	-	-	-	437	-

Cashflow (Last 12 Months)

(In Thousands)

Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	19.7%	-5,013	-6,240	-1,359	5,930	-4,074	-21,909	-13,301	-12,911	-25,637	-19,086	-10,297	55,216	-19,955	-15,572	-19,482	-14,038	-3,093	-9,649	-14,641	-16,651	-569
Share Based Compensation	165.6%	5,134	1,933	1,943	2,172	2,758	4,080	2,707	2,391	3,207	2,339	2,202	2,306	2,639	1,632	1,884	1,757	2,024	1,411	2,098	2,653	2,953
Cashflow From Investing	104.6%	313	-6,874	-1,170	2,970	777	18,598	10,455	21,095	22,629	6,488	-44,397	-49,659	7,532	8,711	19,528	-5,234	24,461	-7,617	-294	-14,672	-1,073
Cashflow From Financing	-616.9%	-2,512	486	-869	-373	19,123	-2,096	5,511	-5,662	8,797	1,085	274	59,219	2,097	667	52.00	10,516	1,336	694	9,799	856	16.00

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

RIGL Income Statement

2024-03-31

CONDENSED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Total revenues	$ 29,534	$ 26,070
Costs and expenses:
Cost of product sales	2,025	977
Research and development	6,026	10,089
Selling, general and administrative	28,449	27,729
Total costs and expenses	36,500	38,795
Loss from operations	(6,966)	(12,725)
Interest income	593	393
Interest expense	(1,874)	(1,204)
Net loss	$ (8,247)	$ (13,536)
Net loss per share, basic (in dollars per share)	$ (0.05)	$ (0.08)
Net loss per share, diluted (in dollars per share)	$ (0.05)	$ (0.08)
Weighted average shares used in computing net loss per share, basic (in shares)	175,203	173,568
Weighted average shares used in computing net loss per share, diluted (in shares)	175,203	173,568
Product sales, net
Total revenues	$ 26,003	$ 23,745
Revenues from collaborations
Total revenues	$ 3,531	$ 2,325

RIGL Balance Sheet

2024-03-31

CONDENSED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 25,574	$ 32,786
Short-term investments	23,976	24,147
Accounts receivable, net	27,512	30,550
Inventories	6,579	5,522
Prepaid and other current assets	8,845	6,261
Total current assets	92,486	99,266
Property and equipment, net	140	165
Intangible asset, net	28,863	13,878
Operating lease right-of-use asset	712	861
Other assets	4,318	3,055
Total assets	126,519	117,225
Current liabilities:
Accounts payable	9,276	7,142
Accrued compensation	5,246	8,676
Accrued research and development	4,127	3,513
Acquisition-related liabilities	15,222
Revenue reserves and refund liability	16,045	15,684
Loans payable, net, current portion	14,780	7,229
Other accrued liabilities	5,435	5,334
Lease liabilities, current portion	709	692
Deferred revenue	1,355	1,355
Other long-term liabilities, current portion	1,003	3,642
Total current liabilities	73,198	53,267
Long-term portion of lease liabilities	100	285
Long-term portion of loans payable, net	44,910	52,373
Other long-term liabilities	39,982	39,944
Total liabilities	158,190	145,869
Commitments
Stockholders' deficit:
Preferred stock
Common stock	175	175
Additional paid-in capital	1,383,956	1,378,723
Accumulated other comprehensive (loss) income	(5)	8
Accumulated deficit	(1,415,797)	(1,407,550)
Total stockholders' deficit	(31,671)	(28,644)
Total liabilities and stockholders' deficit	$ 126,519	$ 117,225

About Rigel Pharmaceuticals Inc

Rigel Pharmaceuticals, Inc., a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company's commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; and Rezlidhia, a non-intensive monotherapy for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test. It also develops Fostamatinib that has conducted phase III clinical trials for the treatment of warm autoimmune hemolytic anemia; has completed FOCUS phase III clinical trial for the treatment of hospitalized high-risk patients COVID-19; and that is in phase II/III clinical trials for the treatment of COVID-19 in hospitalized patients. In addition, the company's other clinical programs include interleukin receptor-associated kinase inhibitor program and a receptor-interacting serine/threonine-protein kinase inhibitor program in clinical development with partner Eli Lilly and Company. Further, it has product candidates in clinical development with partners BerGenBio ASA and Daiichi Sankyo. The company was incorporated in 1996 and is headquartered in South San Francisco, California.

CEO	Mr. Raul R. Rodriguez
WEBSITE	rigel.com
INDUSTRY	Biotechnology
EMPLOYEES	155

Rigel Pharmaceuticals Inc Frequently Asked Questions

What is the ticker symbol for Rigel Pharmaceuticals Inc? What does RIGL stand for in stocks?

RIGL is the stock ticker symbol of Rigel Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Rigel Pharmaceuticals Inc (RIGL)?

As of Wed May 08 2024, market cap of Rigel Pharmaceuticals Inc is 173.65 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of RIGL stock?

You can check RIGL's fair value in chart for subscribers.

What is the fair value of RIGL stock?

You can check RIGL's fair value in chart for subscribers. The fair value of Rigel Pharmaceuticals Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Rigel Pharmaceuticals Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for RIGL so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Rigel Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether RIGL is over valued or under valued. Whether Rigel Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Rigel Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for RIGL.

What is Rigel Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed May 08 2024, RIGL's PE ratio (Price to Earnings) is -8.77 and Price to Sales (PS) ratio is 1.44. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. RIGL PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Rigel Pharmaceuticals Inc's stock?

In the past 10 years, Rigel Pharmaceuticals Inc has provided -0.101 (multiply by 100 for percentage) rate of return.